ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 38045829

Oncofetal reprogramming in tumor development and progression: novel insights into cancer therapy.

Cao J and 9 others. MedComm (2020), 2023. Cited by 21 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Oncofetal reprogramming in tumor development and progression: novel insights into cancer therapy. Papers, record 38045829. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38045829

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Oncofetal reprogramming in tumor development and progression: novel insights into cancer therapy.
PubMed
Journal
MedComm (2020)
PubMed
Year
2023
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
21
iCite
Relative citation ratio, by iCite
1.74
iCite
Revised in PubMed
2023-12-05
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Cao JJiangjun
2Zhang ZZhe
3Zhou LLi
4Luo MMaochao
5Li LLei
6Li BBowen
7Nice ECEdouard C
8He WWeifeng
9Zheng SShaojianghttps://orcid.org/0000-0002-2323-0736
10Huang CCanhua

Source PubMed

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References536

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
115,834,856Anticancer multidrug resistance mediated by MRP1: recent advances in the discovery of reversal agents.Med Res Rev2005https://conductscience.org/library/papers/15834856PubMed
230,885,690Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance.Immunol Lett2020https://conductscience.org/library/papers/30885690PubMed
324,209,616Mechanisms governing metastatic dormancy and reactivation.Cell2013https://conductscience.org/library/papers/24209616PubMed
429,443,960TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.Nature2018https://conductscience.org/library/papers/29443960PubMed
522,472,119CCL2 mediates cross-talk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells.Cancer Res2012https://conductscience.org/library/papers/22472119PubMed
635,716,972Harnessing redox signaling to overcome therapeutic-resistant cancer dormancy.Biochim Biophys Acta Rev Cancer2022https://conductscience.org/library/papers/35716972PubMed
733,681,821The current paradigm and challenges ahead for the dormancy of disseminated tumor cells.Nat Cancer2020https://conductscience.org/library/papers/33681821PubMed
825,119,024Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function.Nature2014https://conductscience.org/library/papers/25119024PubMed
927,197,169The Small Molecule IMR-1 Inhibits the Notch Transcriptional Activation Complex to Suppress Tumorigenesis.Cancer Res2016https://conductscience.org/library/papers/27197169PubMed
1033,995,676Organ-specific cholesterol metabolic aberration fuels liver metastasis of colorectal cancer.Theranostics2021https://conductscience.org/library/papers/33995676PubMed

1 to 10 of 536

See all 536 references

Cited by19

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 21 citations.

PMIDTitleJournalYearIn PapersSource
42,761,580Oncofetal antigens as emerging targets in chimeric antigen receptor (CAR)-T cell-based immunotherapies: opportunities and challenges.Front Cell Dev Biol2026https://conductscience.org/library/papers/42761580PubMed
42,539,001Genetic and Pharmacologic Targeting of Eya3 in Macrophages Drives Anti-Tumor Immunity in Triple-Negative Breast Cancer.bioRxiv2026https://conductscience.org/library/papers/42539001PubMed
42,351,118Antibody-drug conjugates in breast cancer: from mechanism to revolutionizing clinical practice.Mol Cancer2026https://conductscience.org/library/papers/42351118PubMed
42,163,039Uncovering G Protein-Coupled Receptors: Novel Targets and Biomarkers for Predicting Glioma Prognosis.Ann Clin Transl Neurol2026https://conductscience.org/library/papers/42163039PubMed
41,780,553Oncofetal reprogramming in hepatocellular carcinoma: linking developmental programs to cancer vaccines and immunotherapy.Clin Mol Hepatol2026https://conductscience.org/library/papers/41780553PubMed
41,573,850Haruka Resolves Perturbation Response Heterogeneity in Spatial Cell Niches.bioRxiv2025https://conductscience.org/library/papers/41573850PubMed
41,372,484ColoStem, a core oncofetal signature that identifies poor prognosis colorectal tumors.Br J Cancer2026https://conductscience.org/library/papers/41372484PubMed
41,327,404The role of AP2M1 in oncofetal characteristics: integrative in silico, in vitro, and in vivo analyses using zebrafish models.Eur J Med Res2025https://conductscience.org/library/papers/41327404PubMed
40,949,873Identification of oncofetal PIWI-interacting RNAs as potential prognostic biomarkers in non-small cell lung cancer.Front Genet2025https://conductscience.org/library/papers/40949873PubMed
40,770,117A fetal oncogene NUAK2 is an emerging therapeutic target in glioblastoma.EMBO Mol Med2025https://conductscience.org/library/papers/40770117PubMed

1 to 10 of 19

See all 19 cited by

Genes130

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ABCB15,243PubTator's text mininghttps://conductscience.org/library/genes/5243NCBI Gene
ABCB610,058PubTator's text mininghttps://conductscience.org/library/genes/10058NCBI Gene
ABCC14,363PubTator's text mininghttps://conductscience.org/library/genes/4363NCBI Gene
ABCG29,429PubTator's text mininghttps://conductscience.org/library/genes/9429NCBI Gene
ADAM10102PubTator's text mininghttps://conductscience.org/library/genes/102NCBI Gene
ADAM176,868PubTator's text mininghttps://conductscience.org/library/genes/6868NCBI Gene
AKT1207PubTator's text mininghttps://conductscience.org/library/genes/207NCBI Gene
ANXA6309PubTator's text mininghttps://conductscience.org/library/genes/309NCBI Gene
ATF4468PubTator's text mininghttps://conductscience.org/library/genes/468NCBI Gene
AXIN18,312PubTator's text mininghttps://conductscience.org/library/genes/8312NCBI Gene

1 to 10 of 130

See all 130 genes

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/38045829

GET https://conductscience.org/api/papers/v1/38045829/references?page=2

API referenceFor AI assistants